ImmunityBio, Inc. (NASDAQ: IBRX) reported a strong start to 2025, with net product revenue reaching approximately $16.5 million for the first quarter ended March 31, marking a 129% increase from Q4 2024’s $7.2 million. This surge follows the January introduction of a permanent J-code (J9028), simplifying billing and reimbursement for prescribing providers.
Sales of ANKTIVA®, the company’s immunotherapy for bladder cancer, also soared, with unit volumes jumping 150% compared to the previous quarter. March alone saw a 69% increase in monthly unit sales over February, highlighting continued momentum.
ImmunityBio is also seeing growing participation in its recombinant BCG (rBCG) Expanded Access Program, with close to 200 urology practices across the U.S. enrolling. The program addresses the ongoing BCG shortage and expands access to treatment, particularly in rural regions.
At AUA 2025, the company shared promising long-term data from its QUILT 3.032 study, noting durable responses and a high rate of cystectomy avoidance in patients with non-muscle invasive bladder cancer (NMIBC).
To support its expanding operations, ImmunityBio successfully closed a $75 million equity financing round in April 2025.
President and CEO Richard Adcock highlighted the increased adoption of ANKTIVA and the positive impact of the rBCG rollout, emphasizing the company’s commitment to making advanced therapies more widely available.
Explore RevTech News for the latest advancements in Revenue, Business & Marketing Operations with insightful updates from industry experts!
Source: Finance.yahoo.com
